Market Cap 11.38B
Revenue (ttm) 3.81B
Net Income (ttm) 663.00M
EPS (ttm) N/A
PE Ratio 17.83
Forward PE 23.67
Profit Margin 17.40%
Debt to Equity Ratio 0.18
Volume 2,152,000
Avg Vol 2,348,594
Day's Range N/A - N/A
Shares Out 834.65M
Stochastic %K 66%
Beta 0.35
Analysts Hold
Price Target $15.54

Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equival...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900
Address:
8-2-337, Road No. 3, Banjara Hills, Hyderabad, India
MStocktwit
MStocktwit Apr. 30 at 5:20 PM
$NVO $RDY $LLY Exact copy from the Novo with different branded label. Better than a Generic. Approved last year. Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
Gnomsayin
Gnomsayin Apr. 29 at 7:48 PM
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 6:02 PM
$NVO $RDY $LLY Novo changes the label and you have the generic ready to go. Source http://www.endorhealth.com/article/generic-ozempic-coming-to-canada#:~:text=Eli%20Lilly%20has%20stated%20it,rebranded%20versions%20on%20December%2022%3A
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 5:48 PM
$NVO $RDY $LLY In December 2025, Health Canada approved two Novo Nordisk rebranded versions on December 22: Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
ForestFoxes
ForestFoxes Apr. 29 at 5:29 PM
$LLY $NVO $RDY Dr. Reddy's Laboratories (RDY) is strongly connected with Coya Therapeutics $COYA through a strategic partnership, licensing agreement, and financial investment 🙂
0 · Reply
Ro_Patel
Ro_Patel Apr. 29 at 5:26 PM
Health Canada approves $RDY generic version of $NVO Ozempic (patent expired in January) Canada is the first in the G7 forum to approve a generic version of the treatment Also, reviewing 8 other submissions for generic GLP-1 treatments & expects to make regulatory decisions in the coming weeks & months Some generic medications in Canada can be 45% to 90% cheaper than their brand name equivalents A monthly supply of Ozempic or Wegovy costs b/n $300-$400 — sometimes even more depending on the dose A recent survey suggested about 3M Canadian adults are currently taking GLP-1 drugs, such as Ozempic or Mounjaro, and that many more would like to, but cost is a barrier. $LLY
0 · Reply
Nalgenon
Nalgenon Mar. 27 at 12:15 AM
$RDY Do not underestimate future growth from complex drugs rather than basic generics.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 12:55 PM
$RDY RSI: 34.35, MACD: 0.0416 Vol: 0.18, MA20: 14.40, MA50: 13.96 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 4 at 1:25 PM
$RDY Share Price: $14.24 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $1.21 – $1.49 Target Zone: $2.20 – $2.69 Potential Upside: 72% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Fhebre
Fhebre Feb. 25 at 11:09 PM
0 · Reply
Latest News on RDY
Canada gives nod for Dr Reddy’s semaglutide

2026-04-29T21:55:00.000Z - 3 days ago

Canada gives nod for Dr Reddy’s semaglutide


Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic

Wed, 29 Apr 2026 12:37:00 -0400 - 3 days ago

Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic


Dr. Reddy's to announce Q4 and FY26 results on May 12, 2026

2026-04-24T09:09:58.000Z - 8 days ago

Dr. Reddy's to announce Q4 and FY26 results on May 12, 2026


Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs

2026-04-23T19:26:30.000Z - 9 days ago

Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs


Dr. Reddy's (RDY) Shares Surge on Generic Drug News

2026-04-23T17:28:22.000Z - 9 days ago

Dr. Reddy's (RDY) Shares Surge on Generic Drug News


Dr Reddy's board to consider final dividend for FY 2025-26

2026-04-16T10:13:49.000Z - 16 days ago

Dr Reddy's board to consider final dividend for FY 2025-26


What is dragging Dr Reddy’s shares 2% down today? Explained

2026-03-09T04:30:41.000Z - 7 weeks ago

What is dragging Dr Reddy’s shares 2% down today? Explained


Q3 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript

2026-01-25T23:46:06.000Z - 3 months ago

Q3 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript


Dr. Reddy's Q1FY26 Financial Results

Jul 23, 2025, 1:46 PM EDT - 10 months ago

Dr. Reddy's Q1FY26 Financial Results


Dr. Reddy's Q4 & Full Year FY25 Financial Results

May 9, 2025, 2:53 PM EDT - 1 year ago

Dr. Reddy's Q4 & Full Year FY25 Financial Results


Dr. Reddy's Q3 & 9MFY25 Financial Results

Jan 23, 2025, 12:35 PM EST - 1 year ago

Dr. Reddy's Q3 & 9MFY25 Financial Results


Dr. Reddy's Q2 & H1FY25 Financial Results

Nov 5, 2024, 9:59 AM EST - 1 year ago

Dr. Reddy's Q2 & H1FY25 Financial Results


Dr. Reddy's Q1FY25 Financial Results

Jul 27, 2024, 9:51 AM EDT - 1 year ago

Dr. Reddy's Q1FY25 Financial Results


Dr. Reddy's Q4 & Full Year FY24 Financial Results

May 7, 2024, 10:31 AM EDT - 2 years ago

Dr. Reddy's Q4 & Full Year FY24 Financial Results


Dr. Reddy's Q3 & 9M FY24 Financial Results

Jan 31, 2024, 9:44 AM EST - 2 years ago

Dr. Reddy's Q3 & 9M FY24 Financial Results


India's Dr. Reddy's R&D centre being inspected by US FDA

Dec 5, 2023, 4:41 AM EST - 2 years ago

India's Dr. Reddy's R&D centre being inspected by US FDA


Dr. Reddy's Q2 FY24 Financial Results

Oct 27, 2023, 1:50 PM EDT - 2 years ago

Dr. Reddy's Q2 FY24 Financial Results


Dr. Reddy's Q1 FY24 Financial Results

Jul 26, 2023, 12:31 PM EDT - 3 years ago

Dr. Reddy's Q1 FY24 Financial Results


Dr. Reddy's Q4 & FY23 Financial Results

May 10, 2023, 11:43 AM EDT - 3 years ago

Dr. Reddy's Q4 & FY23 Financial Results


Dr. Reddy's: A Profitable, Predictable Margin Expander

May 8, 2023, 12:29 PM EDT - 3 years ago

Dr. Reddy's: A Profitable, Predictable Margin Expander


MStocktwit
MStocktwit Apr. 30 at 5:20 PM
$NVO $RDY $LLY Exact copy from the Novo with different branded label. Better than a Generic. Approved last year. Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
Gnomsayin
Gnomsayin Apr. 29 at 7:48 PM
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 6:02 PM
$NVO $RDY $LLY Novo changes the label and you have the generic ready to go. Source http://www.endorhealth.com/article/generic-ozempic-coming-to-canada#:~:text=Eli%20Lilly%20has%20stated%20it,rebranded%20versions%20on%20December%2022%3A
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 5:48 PM
$NVO $RDY $LLY In December 2025, Health Canada approved two Novo Nordisk rebranded versions on December 22: Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
ForestFoxes
ForestFoxes Apr. 29 at 5:29 PM
$LLY $NVO $RDY Dr. Reddy's Laboratories (RDY) is strongly connected with Coya Therapeutics $COYA through a strategic partnership, licensing agreement, and financial investment 🙂
0 · Reply
Ro_Patel
Ro_Patel Apr. 29 at 5:26 PM
Health Canada approves $RDY generic version of $NVO Ozempic (patent expired in January) Canada is the first in the G7 forum to approve a generic version of the treatment Also, reviewing 8 other submissions for generic GLP-1 treatments & expects to make regulatory decisions in the coming weeks & months Some generic medications in Canada can be 45% to 90% cheaper than their brand name equivalents A monthly supply of Ozempic or Wegovy costs b/n $300-$400 — sometimes even more depending on the dose A recent survey suggested about 3M Canadian adults are currently taking GLP-1 drugs, such as Ozempic or Mounjaro, and that many more would like to, but cost is a barrier. $LLY
0 · Reply
Nalgenon
Nalgenon Mar. 27 at 12:15 AM
$RDY Do not underestimate future growth from complex drugs rather than basic generics.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 12:55 PM
$RDY RSI: 34.35, MACD: 0.0416 Vol: 0.18, MA20: 14.40, MA50: 13.96 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 4 at 1:25 PM
$RDY Share Price: $14.24 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $1.21 – $1.49 Target Zone: $2.20 – $2.69 Potential Upside: 72% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Fhebre
Fhebre Feb. 25 at 11:09 PM
0 · Reply
afterhoursearnings
afterhoursearnings Feb. 25 at 5:11 AM
0 · Reply
Jwa68
Jwa68 Feb. 13 at 1:57 PM
$COYA $RDY $AZN $LLY $NVO Great read. Very well composed. Dr Reddy's and David Einhorn both own 9.9% of the company, just under 20% togethor.
0 · Reply
TalkMarkets
TalkMarkets Feb. 13 at 11:47 AM
Coya Therapeutics Stock Poised To Appreciate As Company Advances Superior ALS Therapy $COYA Also $RDY $AZN $LLY $NVO https://talkmarkets.com/content/stocks--equities/coya-therapeutics-stock-poised-to-appreciate-as-company-advances-superior-als-therapy?post=557175&userid=166882
0 · Reply
Shanna788
Shanna788 Feb. 9 at 4:59 PM
$RDY Company stock current PE 18.60 times, at current price US$14.17, target US$49.85, at PE 59.88 times. The fair USA market PE is 59.88 times [100/(cash deposit return %4.27 minus current inflation rate %2.60)] Other stock positive indicators Operating CF - Positive, shares outstanding (Diluted) - Steady, Revenue, Net profit - Trend up.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 6 at 1:24 AM
$RDY Share Price: $13.97 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $0.69 – $0.85 Target Zone: $1.27 – $1.55 Potential Upside: 74% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CydoniaAnhedonia
CydoniaAnhedonia Feb. 4 at 6:23 PM
$NVO As Dylan said, you gotta serve somebody... so make it $RDY
0 · Reply
CydoniaAnhedonia
CydoniaAnhedonia Feb. 3 at 8:59 PM
$NVO now trading under $RDY
0 · Reply
CydoniaAnhedonia
CydoniaAnhedonia Feb. 2 at 5:40 PM
$RDY I like
0 · Reply
Fhebre
Fhebre Jan. 26 at 6:08 PM
$RDY good entry point
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 3:45 AM
$RDY RSI: 43.15, MACD: -0.1975 Vol: 0.42, MA20: 13.63, MA50: 13.83 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 2:52 PM
$RDY earnings steady but sales stumble — what's next for the stock? Earnings matched estimates, but revenue fell short due to a decline in North America Generics and price erosion. Shares have slipped 9% over the past six months despite the industry’s growth. Understand the risks before investing in RDY 👉 https://www.zacks.com/stock/news/2821086/dr-reddys-q3-earnings-match-estimates-revenues-rise-yy?cid=sm-stocktwits-2-2821086-body-30022&ADID=SYND_STOCKTWITS_TWEET_2_2821086_BODY_30022
0 · Reply
ZacksResearch
ZacksResearch Jan. 22 at 1:38 PM
$RDY Q3 earnings land right on target — but the revenue story raises flags Dr. Reddy’s posted flat Q3 earnings that matched estimates, while revenues missed expectations as global generics growth lagged and North America sales came in weaker. Get the full breakdown and what it means going forward 👉 https://www.zacks.com/stock/news/2821086/dr-reddys-q3-earnings-match-estimates-revenues-rise-yy?cid=sm-stocktwits-2-2821086-teaser-29988&ADID=SYND_STOCKTWITS_TWEET_2_2821086_TEASER_29988
0 · Reply